Journal of Ethnopharmacology, Journal Year: 2024, Volume and Issue: 334, P. 118560 - 118560
Published: July 14, 2024
Language: Английский
Journal of Ethnopharmacology, Journal Year: 2024, Volume and Issue: 334, P. 118560 - 118560
Published: July 14, 2024
Language: Английский
British Journal of Anaesthesia, Journal Year: 2023, Volume and Issue: 131(1), P. 79 - 92
Published: May 18, 2023
Language: Английский
Citations
51Molecular Neurobiology, Journal Year: 2025, Volume and Issue: unknown
Published: March 3, 2025
Language: Английский
Citations
1SAGE Open Medicine, Journal Year: 2024, Volume and Issue: 12
Published: Jan. 1, 2024
Ensuring the proper management of neuropathic pain is a contemporary challenge for professionals who care patients with this type pain. The estimated prevalence in Europe 7%–8%. objective study was to perform non-systematic review on diagnosis, screening, and quantification For purpose, search conducted PubMed/Medline, ScienceDirect, OVID, SciELO databases available evidence. findings highlight common occurrence chronic clinical practice. However, diagnosing managing pose challenges due its complexity individualized nature cases. Precise diagnosis crucial effective management, involving therapeutic approaches that go beyond traditional treatments. It noteworthy until recent times, general questionnaires were utilized assess pain, lacking ability distinguish it from nociceptive or evaluate broader impact well-being. Biomarker panels hold promise identifying treatable causes evaluating treatment effectiveness. In conclusion, describes diagnostic methods tools screening quantifying
Language: Английский
Citations
8International Immunopharmacology, Journal Year: 2024, Volume and Issue: 143, P. 113536 - 113536
Published: Nov. 2, 2024
Language: Английский
Citations
5European Journal of Pain, Journal Year: 2023, Volume and Issue: 28(1), P. 105 - 119
Published: Aug. 11, 2023
Abstract Background Neuropathic pain is common and difficult to treat. The sodium channel blocker lacosamide efficacious in animal models of pain, but its effect on neuropathic humans inconclusive. Methods In a multicentre, randomized, double‐blinded placebo‐controlled phenotype stratified trial, we examined if produced better relief patients with the irritable nociceptor compared those without. primary outcome was change daily average from baseline last week 12 weeks treatment. Secondary tertiary outcomes included relief, patient global impression presence 30% 50% reduction. Results study prematurely closed 93 63 randomized or placebo 2:1 ratio, which 49 fulfilled per protocol criteria used for objective. We did not find phenotype, 95% CI objective 0.41 (−1.2 2.0). For all had no outcome, significantly more were responders than during placebo, an NNT 4.0 (95% 2.3–16.1) 5.0 2.8–24.5) reduction respectively. identify any predictors response. Lacosamide generally well tolerated. Conclusion could confirm that type, closed, so cannot exclude small difference. Significance Treatment often trial error process. Little known about benefit kind medication. shows variable pain. Pain sensory as defined by quantitative testing, predict response treatment lacosamide.
Language: Английский
Citations
13Toxicon, Journal Year: 2023, Volume and Issue: 232, P. 107208 - 107208
Published: June 28, 2023
Language: Английский
Citations
12Pain, Journal Year: 2024, Volume and Issue: 166(1), P. 34 - 41
Published: June 14, 2024
NCT02010281.
Language: Английский
Citations
4European Journal of Pain, Journal Year: 2025, Volume and Issue: 29(2)
Published: Jan. 21, 2025
ABSTRACT Background and Objective Non‐invasive neuromodulation techniques (NIN), such as transcranial Direct Current Stimulation (tDCS) repetitive Transcranial Magnetic (rTMS), have been extensively researched for their potential to alleviate pain by reversing neuroplastic changes associated with neuropathic (NP), a prevalent complex condition. However, treating NP remains challenging due the numerous variables involved, different techniques, dosages aetiologies. It is necessary provide insights clinicians public healthcare managers support clinical decision‐making. This umbrella review aims consolidate existing evidence on effectiveness of various NIN in managing chronic NP. Databases Data Treatment A systematic search was conducted PubMed/MEDLINE database, including meta‐analyses controlled trials comparing sham interventions treatment. The quality included studies assessed using AMSTAR‐2 tool GRADE system, effect sizes adjusted standard mean difference (SMD). Results 22 comprising 8151 participants from 214 trials. most investigated were tDCS rTMS, primary targets being motor cortex dorsolateral prefrontal cortex. findings suggest that excitatory protocols, particularly high‐frequency rTMS anodal tDCS, are effective reducing intensity individuals overall rated low, primarily heterogeneity among small sample sizes. Conclusion show promise NP, benefits reduction. further high‐quality research needed establish optimal protocols long‐term effects. Significance Statement paper consolidates regarding non‐invasive treatment pain, differentiating based aetiology provides easy access this critical information. also highlights key aspects require field pain.
Language: Английский
Citations
0The Lancet Neurology, Journal Year: 2025, Volume and Issue: 24(5), P. 375 - 376
Published: April 16, 2025
Language: Английский
Citations
0La Presse Médicale, Journal Year: 2024, Volume and Issue: 53(2), P. 104233 - 104233
Published: April 16, 2024
Language: Английский
Citations
3